---
title: Regeneron (REGN) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/regn
ticker: REGN
as_of: 2026-10-17
sector: Healthcare
industry: Biotechnology
---
# Regeneron (REGN)

Regeneron (REGN) closed at $790.74 on Oct 16, 2026, undervalued by 24% vs its model value of $1,040.27 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $790.74 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $1,040.27 |
| Price vs model | undervalued by 24% vs model |
| Range of that model | $582.31 – $2,403.32 |
| Market value | $81.4B |
| P/E (fiscal 2025) | 19.1 |
| Net margin (fiscal 2025) | 31.4% |
| Free cash flow (fiscal 2025) | $4.1B |
| Dividend yield (trailing twelve months) | 0.47% |
| Beta | 0.24 |
| Cost of capital (WACC) | 7.05% |
| Business classification | Profitable Growth (Low/slowing growth (~5% recent), High profitability (31% net margin), Moderately volatile earnings, Strong FCF yield (5.0%)) |

## Dividends

| Figure | Value |
| --- | ---: |
| Trailing dividend yield | 0.47% |
| Dividends per share, last 12 months | $3.70 |
| Dividends / free cash flow (fiscal 2025) | 9.1% |
| Raised | — |
| Growth | — |
| Latest payment | $0.94, ex-date Aug 18, 2026, paid Aug 31, 2026 |

| Year of payments | Dividends per share |
| --- | ---: |
| Trailing twelve months (to Aug 18, 2026) | $3.70 |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $1,040.27 | $582.31 | $2,403.32 |
| DCF · Perpetuity growth · 10y | cross check | $1,088.31 | $626.19 | $2,523.43 |
| DCF · EBITDA exit · 5y | cross check | $916.21 | $673.95 | $1,201.55 |
| DCF · EBITDA exit · 10y | cross check | $975.78 | $699.35 | $1,343.96 |
| P/E · peers | cross check | $1,096.21 | $1,024.43 | $1,099.23 |
| P/E · own history | cross check | $935.21 | $731.18 | $1,070.71 |
| PEG | sanity check | $850.06 | $850.06 | $850.06 |
| EV/EBITDA · peers | cross check | $697.74 | $609.85 | $764.37 |
| EV/Revenue · peers | cross check | $980.06 | $605.88 | $1,092.80 |
| Earnings power value | cross check | $474.11 | $392.72 | $599.52 |
| Dividend discount | cross check | $124.76 | $73.24 | $308.02 |

## Insider activity (SEC Form 4)

Past 90 days: 0 open-market buys ($0) and 30 open-market sales ($5.5M); 10b5-1 plan sales included.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Oct 13, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Option/RSU exercise (10b5-1 plan) | 17,000 | $0 |
| Oct 14, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Open-market sell (10b5-1 plan) | 50 | $39,073.5 |
| Oct 14, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Open-market sell (10b5-1 plan) | 463 | $361,431.7 |
| Oct 14, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Open-market sell (10b5-1 plan) | 380 | $296,244.2 |
| Oct 14, 2026 | MURPHY ANDREW J | Co-Chief Scientific Officer | Open-market sell (10b5-1 plan) | 454 | $353,502.6 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Oct 6, 2026 | 8-K | 1.01 Entry into a Material Agreement; 2.02 Results of Operations (Earnings); 8.01 Other Events | https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/tm2627077d1_8k.htm |
| Sep 30, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/872589/000110465926112340/tm2626090d1_8k.htm |
| Jul 30, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm |
| Jul 30, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/regn-20260730.htm |
| Jul 6, 2026 | 8-K | 2.02 Results of Operations (Earnings) | https://www.sec.gov/Archives/edgar/data/872589/000110465926080562/tm2619682d1_8k.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Dodge & Cox | 2026-06-30 | 4,871,137 | $3.0B |
| Mason Hawkins | 2026-06-30 | 152,322 | $95.0M |
| Harry Burn | 2026-06-30 | 126,994 | $79.2M |
| Bridgewater | 2026-06-30 | 51,333 | $32.0M |

4 tracked managers in all.

## About

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV…

---

Source: https://sweetvaluelab.com/stocks/regn (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.